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Abstract
Background: Rheumatic diseases are one of the most common chronic diseases worldwide. Among them, spondyloarthritis
(SpA) is a group of highly debilitating diseases, with an early onset age, which significantly impacts patients’ quality of life,
health care systems, and society in general. Recent treatment options consist of using biologic therapies, and establishing the
most beneficial option according to the patients’ characteristics is a challenge that needs to be overcome. Meanwhile, the emerging
availability of electronic medical records has made necessary the development of methods that can extract insightful information
while handling all the challenges of dealing with complex, real-world data.
Objective: The aim of this study was to achieve a better understanding of SpA patients’ therapy responses and identify the
predictors that affect them, thereby enabling the prognosis of therapy success or failure.
Methods: A data mining approach based on joint models for the survival analysis of the biologic therapy failure is proposed,
which considers the information of both baseline and time-varying variables extracted from the electronic medical records of
SpA patients from the database, Reuma.pt.
Results: Our results show that being a male, starting biologic therapy at an older age, having a larger time interval between
disease start and initiation of the first biologic drug, and being human leukocyte antigen (HLA)–B27 positive are indicators of a
good prognosis for the biological drug survival; meanwhile, having disease onset or biologic therapy initiation occur in more
recent years, a larger number of education years, and higher values of C-reactive protein or Bath Ankylosing Spondylitis Functional
Index (BASFI) at baseline are all predictors of a greater risk of failure of the first biologic therapy.
Conclusions: Among this Portuguese subpopulation of SpA patients, those who were male, HLA-B27 positive, and with a later
biologic therapy starting date or a larger time interval between disease start and initiation of the first biologic therapy showed
longer therapy adherence. Joint models proved to be a valuable tool for the analysis of electronic medical records in the field of
rheumatic diseases and may allow for the identification of potential predictors of biologic therapy failure.
(JMIR Med Inform 2021;9(7):e26823) doi: 10.2196/26823
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Rheumatic diseases are chronic diseases that, being the leading
cause of disability in developed countries, consume many health
and social resources. Among these diseases, spondyloarthritis
(SpA) is a group of several related disorders that can be highly
debilitating and significantly impact patients' quality of life,
health care systems, and society [1].
As there is no cure, treatment focuses on the relief of symptoms
and the delay of the disease's progression. Biologic therapies
are the most recent approach for treating these disorders, and
their use is recommended when all other methods have failed.
However, the therapy selection follows no specific criteria, and
trying to establish which patients benefit the most from each
drug is still a problem that needs to be solved [2].
A better understanding of therapy responses for these patients
and identifying the predictors that affect these responses would
allow for a prognosis of therapy success or failure and thus be
highly valuable in conserving the resources and time of both
patients and medical doctors. Moreover, this understanding
could be used to aid medical experts in tailoring the treatment
to the patient by using a more personalized approach.
Meanwhile, the emerging availability of electronic medical
records has enabled the storage of great amounts of information
that can be used to extract insightful knowledge. Data mining
is a rapidly growing field that focuses on developing the
techniques necessary for insightfully using this information.
The analysis of an outcome of interest is usually performed
using survival analysis methods. such as the Kaplan-Meier
estimator [3] and the Cox model [4]. Nevertheless, these
methods are only able to deal with time-static variables. For
dealing with time-varying variables, methods such as the
extended Cox model [5] have been introduced. However, they
are not appropriate for dealing with biomarkers [6,7].
Joint models have been presented in the literature as a useful
approach for handling these types of analysis, having been used
in a wide range of medical studies, including the most common
disease areas of cancer and HIV and AIDS [8].
In the field of rheumatic diseases, these joint modeling and
machine learning approaches were studied to evaluate the
clinical impact on flare occurrence in patients undergoing
biologic treatments for rheumatoid arthritis. Both models were
proven to assist in decisions on biologic dose reduction with
the potential to reduce the occurrence of flares significantly [9].
The development of juvenile dermatomyositis was also studied
using longitudinal approaches, allowing for a better perception
of longitudinal outcomes and a more accurate comprehension
of predictors' effects [10].
However, the use of these methods has been less explored for
other diseases in this field, such as SpA.
Our main goal was to propose a data mining approach based
on joint models to infer relationships between time-to-event
and longitudinal electronic medical record data, retrieved from
the Rheumatic Disease Portuguese Register (Reuma.pt) [11].
We further aimed to study the predictors of failure of the first
biologic therapy for patients with SpA and verify the




Spondyloarthritis is the name given to a family of inflammatory
rheumatic diseases that share distinctive pathophysiologic,
clinical, radiographic, and genetic features. This includes
ankylosing spondylitis (AS)—the characteristic type of this
group—psoriatic arthritis, reactive arthritis, enteropathic
arthritis, and so called undifferentiated SpA.
AS is characterized by chronic inflammation predominantly
affecting the axial skeleton. Although its pathogenesis is poorly
understood, there is a strong association between AS and the
human leukocyte antigen B27 (HLA-B27), and the typical age
at onset of this condition is at the second or third decade of life
[12].
The first population-based study on rheumatic diseases in
Portugal, EpiReumaPt, reported the national health survey
results in 2015, revealing a general SpA prevalence of 1.6%
and a prevalence of 2.0% and 1.2% for women and men,
respectively [1].
The socioeconomic impact can be rather high for these
conditions. A recent study [13] revealed that AS has a total
annual economic impact of €639 million (US $773 million) in
Portugal. This value includes the disease-related costs for the
patient and the national health system and the economic impact
of the lost workdays.
Clinical monitoring of a disease is of extreme importance to
understanding disease progression, better assessing patient
response to treatment, and guiding therapeutic decisions.
Laboratory exams include erythrocyte sedimentation rate (ESR)
and levels of C-reactive protein (CRP), which are markers of
inflammation, and other laboratory data that are considered to
show relevant alterations.
Functional ability can be evaluated using the Bath Ankylosing
Spondylitis Functional Index (BASFI) [14] score, and activity
disease can be evaluated using the Bath Ankylosing Disease
Status in Ankylosing Spondylitis (BASDAI) score [15] or the
more recently developed Ankylosing Spondylitis Disease
Activity Score (ASDAS) [16]. The ASDAS has two different
formulas, ASDAS-CRP (which uses the C-reactive protein) and
ASDAS-ESR (which uses ESR), with ASDAS-CRP usually
being the preferred system.
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Treatment of SpA should be tailored to the patient, and patient
signs, symptoms, and characteristics should be taken into
account, with the most common goal being the attainment of a
state of inactive disease.
Treatment options can include physical therapy, nonsteroidal
anti-inflammatory drugs, disease-modifying antirheumatic drugs,
and, if patients remain in a high disease activity state when
trying the referred options, treatment with biologic agents,
namely tumor necrosis factor inhibitors and interleukin-17 or
interleukin-23 inhibitors.
Time-to-Event Analysis
Survival analysis, or time-to-event analysis, is the collection of
statistical procedures for the analysis in which the outcome
variable of interest is the time until an event occurs.
Let T denote a random, nonnegative, continuous variable
representing the patient’s survival time and let t be an observed
value of T.
The hazard function can be interpreted as the instantaneous
potential per unit time for the event to occur, given that the
individual has survived to time t. It is calculated as follows:
The main feature that distinguishes survival data from other
types of data is the possible presence of censored survival times.
Considering a specific individual i, let Ti be the random variable
representing its true survival time and Ci the potential censoring
time. With consideration to right censoring, the censoring
indicator variable, δi, is defined as δi = I(Ti ≤ Ci), where I (. ) is
the indicator function.
The Cox proportional hazards model [4] allows us to estimate
the hazard function and explore how the survival of a group of
patients depends on the values of one or more explanatory
variables.
Let x = (x1, x2, … , xk) be the values of the k explanatory
variables of an individual and β = (β1, β2, …, βk) the vector of
its correspondent unknown regression coefficients. The hazard
function is given by the following:
h(t; x) = h0 (t)exp (βTx)
where h0 (t) is the baseline hazard function, representing the
hazard for a patient when its vector of explanatory variables is
equal to zero (x = 0).
It is possible to extend the previously presented Cox model for
handling time-dependent variables [5]. This model is referred
to as the extended Cox model. However, it is not theoretically
appropriate to deal with biomarkers since it assumes that the
time-dependent variables are predictable processes, measured
without error and with a full path completely known.
Longitudinal Analysis
Longitudinal data can be defined as the data obtained from
multiple measurements of individuals throughout time.
Linear mixed effects (LME) models are a common way of
modeling this data. In an LME model, the individual’s response
is assumed to follow a linear regression model where some of
the regression parameters are population specific and others are
patient specific. These are referred to as fixed effects and
random effects, respectively [17].
Let Yi be the ni-dimensional response vector for subject i. In
general, a linear mixed-effects model satisfies the following:
where β is a p-dimensional vector that contains the fixed effects;
bi is the q-dimensional vector containing the random effects,
and  i is a ni-dimensional vector of random errors; Xi and Zi are
the (ni × p) and (ni × q) fixed-effects and random effects design
matrices, respectively; D is a (q × q) positive-definite covariance
matrix; and Σi is a (ni × ni) positive-definite covariance matrix
that depends on i through its dimension ni. The εi is normally
distributed with mean zero and covariance matrix D, and bi is
normally distributed with mean zero and covariance matrix Σi.
Both bi and εi are assumed to be independent of each other and
of groups [17].
Joint Models for Longitudinal and Time-to-Event Data
The basic idea of joint models is to perform combined analysis,
in which a relative risk model is estimated for the time-to-event
outcome, taking into account the effect of the longitudinal data
measurements—this is usually done by combining a survival
model with a mixed-effects model [6].
The first step is modeling the continuous longitudinal outcomes
with LME models. Let yk denote the (nki × 1) longitudinal
response vector for the k-th outcome (k = 1, … , K) and the i-th
subject that is composed by elements ykil,which represent the
value of the k-th longitudinal outcome taken at time point tkil.
Let bki be a vector of random effects and βk a vector of fixed
effects. We have that the conditional expectation of yk given
bki, ηki (t) is modeled through the LME model as follows:
where xki (t) and zki (t) are the design vectors for the random
and fixed effects, respectively.
Let be the true event time for the i-th subject. We can now
postulate the relative risk model for the survival process as
follows:
where Mi (t) = {M1i (t), …, Mki (t)} and Mki(t) = {ηki (s), 0 ≤ s
< t} denotes the history of the true unobserved longitudinal
process up to time point t, h0(. ) denotes the baseline risk
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function, and wi(t) is a vector of exogenous covariates with a
corresponding vector of regression coefficients γ. The fkl
functions, parametrized by vector αkl, specify which components
of each longitudinal outcome will be present in the relative risk
model, allowing up to Lk functional forms for each of K
longitudinal outcomes. The parameters contained in αkl quantify
the effect of the correspondent underlying longitudinal outcome
to the risk for an event.
One of the basic approaches for the functional form is to model
the event's hazard as having an association only with the current
value of the longitudinal outcome at the same time point.
Considering a single outcome, this is given by f{α, wi(t), bi,
Mi(t)} = αηi(t), where α is the strength of association parameter
that indicates the change in the log hazard when there is a unit
change in the patient’s longitudinal outcome value.
Estimation of joint models is performed by exploiting the full
joint likelihood that is derived from the joint distribution of the
longitudinal and survival outcomes. Methods for this estimation
can follow, among others, a frequentist or a Bayesian paradigm
[18,19].
Methods
SpA Patients on Biologic Therapies: Data Description
and Preprocessing
The data used in this study were retrieved from Reuma.pt [11]
on July 22, 2019. This register was developed by the Portuguese
Society of Rheumatology, has been active since June 2008, and
contains information retrieved on a routine basis of rheumatic
patients in Portugal receiving biological therapies. Although
Reuma.pt also contains patients with several rheumatic diseases,
the focus of this work was on patients with SpA.
With the data extracted from this database, 4 different data sets,
A, B, C and D, were obtained according to different strategies
for handling the missing values. A set of different joint models
was then fitted to all data sets, as well as the equivalent extended
Cox models using R software (The R Foundation for Statistical
Computing) [20], namely packages “JM” [18] and “Jmbayes”
[19]. This resulted in a total of 49 joint models and 29 extended
Cox models. All the steps of the data processing and modeling
framework are described in detail in this section.
The Reuma.pt database contains information regarding patients
and patient visits, including identification data, demographic
data, previous medical history, comorbidities, laboratory results,
past and current therapies, adverse events, and disease activity
scores, among others.
The follow-up of patients through this registry enables the
monitoring of treatment efficacy, safety, and comorbidities.
The goal of this work was to perform a survival analysis that
takes into account both time-independent and time-dependent
variables and understand how these impact the outcome of
interest. Therefore, 3 types of variables were needed:
time-independent (baseline) variables, time-dependent variables,
and time-to-event variables. The latter type is not directly found
in the database and therefore needed to be processed from the
existing data.
Our event of interest was the failure of the first biological
therapy for each patient, where failure was defined as the
discontinuation of the biological therapy due to inefficacy
(evaluated by ASDAS) or adverse events (such as infection or
hypersensitivity).
In this context, the time-to-event variables indicated if the
biologic therapy failed or if the patient was
censored—henceforth referred to as the failure index. The time
until the occurrence of either failure index is referred to as time
to failure.
The data extracted from the database had to go through several
preprocessing steps in order to reach a format compatible with
the models to be fitted.
First, a set of variables to be considered was selected, with 3
main aspects being taken into account: level of missing values,
relevance to the study, and variable equivalence. Variables with
more than 60% of values missing were not considered nor were
variables that were considered to be irrelevant for the goal of
our study as determined according to the feedback given by
medical specialists. Furthermore, some variables available in
the raw data set were equivalent in the sense that they
represented the same information.
After this set of assumptions and processing steps, we obtained
our initial data set, which consisted of the following 3 variables:
1. Time-to-event variables—time to failure and failure index;
2. Time-independent variables—sex, marital status, year of
diagnosis, age at diagnosis, year of disease beginning, age
at disease beginning, year of start of the first biologic
therapy, age at start of the first biologic therapy, years from
diagnosis to start of the first biologic therapy, disease years
until start of the first biologic therapy, HLA-B27,
employment status before disease, employment status at
baseline, years of education, smoking habits, alcohol
consumption habits, weight, height, BMI, number of
pathologies, biologic therapy, concomitant
disease-modifying antirheumatic drug at baseline,
concomitant corticoid at baseline, baseline CRP, baseline
ESR, baseline BASDAI, baseline BASFI, and baseline
ASDAS;
3. Time-dependent variables—CRP, ESR, BASDAI, BASFI,
and ASDAS.
The ASDAS we refer to here and henceforth is the one that
incorporates the CRP value into its calculation and corresponds
to the ASDAS-CRP.
A thorough inspection of all variables was made to identify any
incomplete or incorrect values. Some examples of issues that
arose were values with incorrect formats or incoherent with
these variables’ possible range. If possible, by crossing
information and with medical professionals’ help and
consultation, the values were corrected, but whenever it was
impossible to draw conclusions, the observations were
eliminated.
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In the presented initial data set, not all patients have every
baseline variable available. This poses an issue and is a
challenge that needs to be dealt with in most studies that use
data from clinical settings. The issue arises because most
methods of variable selection and statistical models cannot
handle missing values. Therefore, to further proceed with our
analysis, we needed to understand the different approaches that
can be used to handle this problem according to our needs.
Common approaches include performing complete-case analysis,
removing individuals with incomplete data for a subset of
covariates, and multiple imputation techniques.
We decided not to perform any imputation techniques, as the
imputation of baseline variables could introduce a high bias in
our models’ estimates.
On the other hand, there is always value in keeping the most
amount of data as possible to avoid wasting relevant
information.
As there was no obvious choice regarding which approach would
be the most appropriate and to enable the drawing of valuable
insights from the data, the decision to create 4 different data
sets, according to different approaches, was made. Furthermore,
this allowed us to study how the strategy for handling missing
data and the resulting data differences can influence the
modeling process and the subsequent results. The overall process
for the creation of these data sets is depicted in Figure 1.
The first approach consisted of keeping only the patients for
whom all baseline variables were available (ie, keeping only
the complete cases).
The second approach was to consider only the variables with
fewer than 40% of missing values and then keeping the complete
cases of those variables. The percentage of 40% was chosen
since it seemed to provide a good balance between the number
of eliminated variables and the number of eliminated patients.
The third approach consisted of fitting a univariate Cox model
for each initial baseline variable and then keeping only the
statistically significant ones in those models,\ according to a
5% level. After that, the complete cases of those variables were
once again kept.
The last approach was to keep only those variables that were
considered clinically relevant by expert medical doctors’
knowledge and according to insight from literature research
where predictors of biologic drug survival in SpA were studied
[21-23].
The variables selected for consideration were sex, disease years
to first biologic therapy, age at start of the first biologic therapy,
education years, baseline CRP, baseline BASDAI, and baseline
BASFI. Variables age at start of the first biologic therapy and
baseline BASDAI were later dropped due to violation of the
proportional hazards assumption.
Figure 1. Flowchart representing the overall approach for the preprocessing of the initial data into 4 new data sets: A, B, C, and D.
Statistical Model Implementation
For the initial data set, both an overall survival curve and curves
for survival according to the biologic therapy were fitted with
the Kaplan-Meier estimator [3].
Regarding the 4 processed data sets, the same approach was
used for all data sets, which proceeded as follows.
The first step in the analysis was to perform variable selection
for the baseline covariates. This removed any unnecessary
predictors that could have added noise to the estimations.
Five different methods were used to compare and study the
variability of the obtained results. These were backward stepwise
selection using Akaike information criterion (AIC), forward
stepwise selection using AIC, best subset selection using a
JMIR Med Inform 2021 | vol. 9 | iss. 7 | e26823 | p. 5https://medinform.jmir.org/2021/7/e26823
(page number not for citation purposes)
Barata et alJMIR MEDICAL INFORMATICS
XSL•FO
RenderX
primal-dual active set approach, lasso regression, and the
stepwise likelihood ratio variable selection strategy presented
by Collett [24].
Despite this, the variables obtained from the stepwise likelihood
ratio variable selection were the ones ultimately selected for the
next steps of the analysis, namely for building the survival
submodel.
This variable selection was not performed for data set D, as the
medical experts selected the variables of interest for this specific
case.
A Cox model for the survival submodel was then fitted using
the selected baseline covariates, constituting the survival
submodel.
For each of the time-dependent variables, 7 different LME
models were fitted. The one with the better fit according to AIC
and Bayesian information criterion was chosen as the
time-dependent submodel.
The formulae of the different LME models fitted and the
corresponding names are presented in Table 1.
Having both submodels, the same joint models were fitted with
R packages “JM” [18] and “Jmbayes” [19]. The former estimates
the model under a maximum likelihood approach and the latter
under a Bayesian approach, more specifically, using Markov
chain Monte Carlo algorithms.
The R package “Jmbayes” also enables the fitting of multivariate
joint models. Considering that variables CPR and ESR are both
measurements of inflammation and that ASDAS uses CRP and
BASDAI elements in its composition, we chose not to fit
together CRP with ESR or ASDAS with CRP and BASDAI.
Thus, 2 different combinations of time-dependent variables
were considered for the multivariate joint models: CRP,
BASDAI, and BASFI; and BASFI and ASDAS.
The equivalent models, both univariate and multivariate, were
also fitted with an extended Cox model, which enabled the
comparison of both methods.
Should a case arise where the survival submodel contained any
of the variables of baseline CRP, baseline ESR, baseline
BASDAI, baseline BASFI, or baseline ASDAS, these baseline
variables would be dropped when the correspondent
time-dependent variable was present in the univariate joint
model or extended Cox model. This would enable us to compare
the effect of the variable in its baseline form with its
time-dependent form. Similarly, if more than one of the 5
baseline variables were present in the survival submodel, a
multivariate joint model or extended Cox model would also be
fitted with those variables in the time-dependent form, and the
baseline form would be dropped from the survival submodel.
The overall process for fitting the joint models and extended
Cox models is schematically presented in Figure 2 and Figure
3, respectively, where it is also possible to observe the numbers
given to the models that were fitted for every data set.
The exhaustive tests performed attempted to cover several types
of strategies and models, and were aimed at identifying key
covariates involved in the prognosis of the disease, particularly
in the response to treatment. Indeed, the rationale for this
approach was to comprehensively span the described methods
due to the fact that this specific Reuma.pt data set did not contain
any prior studies that focused on the identification of specific
markers for the prognosis of the patient’s therapy response.
All the analysis was performed using R software [20],
particularly, the “MASS” [25], “BeSS” [26], and “glmnet” [27]
packages for the forward and backward stepwise variable
selection, best subset selection, and lasso regression,
respectively. Furthermore “car” [28] was used for
multicollinearity testing; “survival” [29] for the Kaplan-Meier
curves, Cox model, extended Cox model, and proportional
hazards testing; “survminer” [30] for the plotting of survival
curves; “nlme” [31] for fitting the linear mixed-effects models;
and “JM” [18] and “Jmbayes” [19] for fitting the joint models.
Table 1. Time-dependent functions used given a time-varying variable y. NC represents natural cubic spline function; β, fixed effects, b, random
effects; and t, time.
Time-dependent functionsModel
β0 + β1tij + bi0 + εijLinear and random intercept
β0 + β1tij + bi0 + bi0tij + εijLinear and random slope
β0 + β1tij+ + bi0 + εij
Cubic and random intercept
β0 + β1tij+ + bi0 + bi1tij + εij
Cubic and random slope
NC(tij, 2, (β0, β1, β2, β3)
T, (bi0) +εij)Spline and random intercept
NC(tij, 2, (β0, β1, β2, β3)
T, (bi0, bi1)
T +εij)Spline and random slope
NC(tij, 2, (β0, β1, β2, β3)
T, (bi0, bi1, bi2, bi3)
T +εij)Spline and random spline
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Figure 2. Flowchart representing the overall approach for the data analysis using univariate and multivariate joint modeling. The variable selection
step is not performed for data set D. ASDAS: Ankylosing Spondylitis Disease Activity Score; BASDAI: Bath Ankylosing Spondylitis Disease Activity
Index; BASFI: Bath Ankylosing Spondylitis Functional Index; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate. *This model is only fitted
for data set D.
Figure 3. Flowchart representing the overall approach for the data analysis using univariate and multivariate extended Cox modeling. The variable
selection step is not performed for data set D. ASDAS: Ankylosing Spondylitis Disease Activity Score; BASDAI: Bath Ankylosing Spondylitis Disease
Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate. *This model is
only fitted for data set D.
Ethics Approval and Consent To Participate
Reuma.pt was approved by the National Data Protection Board
(Comissão Nacional de Protecção de Dados, Portugal) and by
the Ethics Committee of Centro Hospitalar Lisboa Norte,
Hospital de Santa Maria, Lisbon, Portugal. Patients signed
Reuma. pt's informed and written consent.
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Initial SpA Data Set
The survival probability curve, , of the first biologic
therapy for the overall population from the initial data set
obtained with the Kaplan-Meier estimator is presented in Figure
4, where vertical ticks along the curve indicate censored patients.
We can observe that the slope of the curve is higher at the initial
months, indicating that there are more failures closer to the
beginning of the therapy.
A comparison of the survival probabilities between the different
biologic therapies can be seen in Figure 5, where it is possible
to observe a clear distinction between the different biologic
drugs' curves. The P value of the log-rank test is also presented
in the figure, indicating that the biologic drug curves differ
significantly in survival at a 5% level.
A comparison of the survival probabilities between the different
biologic therapies can be seen in Figure 5, where the survival
curves for the different biologics were estimated using the
Kaplan-Meier method. It is also possible to observe the P value
of the log-rank test, whose null hypothesis is that all the groups
have identical hazard functions. As this value is equal to .03,
we can reject this hypothesis at a 5% level of significance.
The pairwise log-rank tests with corrections for multiple testing
were also performed for all pairs of biologics to better compare
the survival of the therapy between biologics. According to the
tests, only 1 pair, etanercept and golimumab, had significantly
different survival curves. An analysis of the curve indicates that
golimumab conferred better survival than did etanercept at a
5% level of significance.
It should also be noted that in the Portuguese SpA subpopulation
studied, there were some biologic drugs that had a very small
number of observations. This difference in number of
observations between different drugs could have also increased
the difficulty in properly comparing the survival between them.
Figure 4. Kaplan-Meier estimation of the biologic therapy survival curve for the overall population of the initial data set with the 95% CI [5].
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Figure 5. Kaplan-Meier estimation of the biologic therapy survival curve by biologic drug for the initial data set and P value of the correspondent
log-rank test with the 95% CI [5].
Figure 6. Coefficient signs of the covariates present in the survival submodels fitted with a Cox regression for data sets A, B, C, and D. BASFI: Bath
Ankylosing Spondylitis Functional Index; CRP, C-reactive protein: HLA-B27, human leukocyte antigen B27.
Comparison of Results: Data Sets A, B, C, and D
The first main step of the modeling process consisted of
selecting the baseline variables of interest.
The comparison of the selected variables only took data sets A,
B, and C into consideration. The percentage of times a variable
was selected for each data set, considering the 5 variable
selection approaches tested, is presented in Table 2, along with
the average number of times it was selected overall.
Although not all variables were present in every data set, the
variability in the covariates selected for each set of data was
still noticeable. This indicates that the initial process of handling
the missing values and the initial selection of variables to be
considered at this stage have a somewhat elevated influence on
the results that are obtained later; in short, the results are
sensitive to the parameter choice. This difference may be
justified by the existence of different variables and even different
patients even if many are common between data sets.
Only 1 variable was selected by all methods and for all data
sets where it was considered: years of education. On average,
the variables that were selected in at least more than 50% of the
methods used for variable selection were year of disease onset,
age at start of the first biologic therapy, baseline BASFI, and
baseline ASDAS.
Table 3 shows the sign of the coefficient for each of the
covariates that were included in the survival submodel for each
data set. The sign of the respective coefficient indicates the
effect of this covariate on the outcome of interest, which we
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took as the failure of the first biologic therapy. A positive sign
indicates that the variable increases the risk of failure for higher
values of that variable (for a continuous variable) or for that
value in comparison to the reference level (for a categorical
variable); a negative coefficient indicates the opposite: a
decrease in the risk of failure.







601002060Year of disease onset
20N/A2020Age at disease onset
40206040Year of start of the first biologic therapy
50N/A4060Age at start of the first biologic therapy
20N/A2020Years from diagnosis to start of the first biologic therapy
20N/A2020Disease years until start of the first biologic therapy
47100400HLA-B27b
30N/A2040Employment status before disease

















bHLA-B27: human leukocyte antigen B27.
cDMARD: disease-modifying antirheumatic drug.
dCRP: C-reactive protein.
eESR: erythrocyte sedimentation rate.
fBASDAI: Bath Ankylosing Spondylitis Disease Activity Index.
gBASFI: Bath Ankylosing Spondylitis Functional Index.
hASDAS: Ankylosing Spondylitis Disease Activity Score.
JMIR Med Inform 2021 | vol. 9 | iss. 7 | e26823 | p. 10https://medinform.jmir.org/2021/7/e26823
(page number not for citation purposes)
Barata et alJMIR MEDICAL INFORMATICS
XSL•FO
RenderX






+Year of disease beginning
++Year of start of the first biologic therapy
–Age at start of the first biologic therapy





aHLA-B27: human leukocyte antigen B27.
bCRP: C-reactive protein.
cBASFI: disease-modifying antirheumatic drug.
It can be noticed that the sign of the coefficient is coherent
between the data sets for all variables even if the number of
data sets where that variable is present differs.
According to the results obtained in the Cox regression, the
factors that indicate a good prognosis for the biologic drug
survival were being a male, starting the biologic therapy at an
older age, having a larger time interval between disease start
and initiation of the first biologic therapy, and being HLA-B27
positive. On the contrary, a disease onset or initiation of biologic
therapy in more recent years, a higher number of years of
education, and higher values of CRP or BASFI at baseline were
all predictors of a greater risk of failure of the first biologic
therapy.
Given the elevated number of models fitted and to aid in the
drawing of comprehensive conclusions, Table 4 and Table 5
were created to depict the joint and extended Cox models,
respectively. For each data set and for every variable present in
the model, the tables show the percentage of models (relative
to the total number of fitted models for each data set) in which
the covariate was statistically significant, the percentage of
models in which the variable had a positive regression
coefficient, and the percentage of models in which the variable
had a negative regression coefficient. Furthermore, the average
of these percentages was calculated to obtain an overall view
of the most common behavior of each variable as determined
by information gathered from all data sets.
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Table 4. Percentage of models in which a variable was statistically significant; percentage of models in which a variable had a positive coefficient
sign; the percentage of models in which a variable had a negative coefficient sign for the covariates present in the joint models fitted for data sets A, B,
C, and D; and the average of those percentages across all data sets.




257592N/AN/AN/A257592N/AN/AN/AN/AN/AN/AYear of disease onset
455283N/AN/AN/AN/AN/AN/A256783643682Year biologic therapy initiation
100082N/AN/AN/AN/AN/AN/AN/AN/AN/A100082Age at start of the first biologic
therapy











ass: percentage of models in which variable is statistically significant.
bpos: percentage of models in which variable has positive coefficient.
cneg: percentage of models in which variable has negative coefficient.
dN/A: not applicable.
eHLA-B27: human leukocyte antigen B27.
fCRP: C-reactive protein.
gBASFI: Bath Ankylosing Spondylitis Functional Index.
hESR: erythrocyte sedimentation rate.
iBASDAI: Bath Ankylosing Spondylitis Disease Activity Index.
jASDAS: Ankylosing Spondylitis Disease Activity Score.
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Table 5. Percentage of models in which a variable was statistically significant; percentage of models in which a variable had a positive coefficient
sign; and percentage of models in which a variable had a negative coefficient sign for the covariates present in the extended Cox models fitted for data





0100100N/AN/AN/A0100100N/AN/AN/AN/AN/AN/AYear of disease onset
0100100N/AN/AN/AN/AN/AN/A01001000100100Year of biologic therapy initiation
100086N/AN/AN/AN/AN/AN/AN/AN/AN/A100086Age at start of the first biologic
therapy











ass: percentage of models in which variable is statistically significant.
bpos: percentage of models in which variable has positive coefficient.
cneg: percentage of models in which variable has negative coefficient.
dN/A: not applicable.
eHLA-B27: human leukocyte antigen B27.
fCRP: C-reactive protein.
gBASFI: Bath Ankylosing Spondylitis Functional Index.
hESR: erythrocyte sedimentation rate.
iBASDAI: Bath Ankylosing Spondylitis Disease Activity Index.
jASDAS: Ankylosing Spondylitis Disease Activity Score.
This consensus or ensemble approach was conducted to facilitate
the identification of the most significant variables. The rationale
is that if a feature always appears as significant, independently
of the specific chosen model, then there is evidence that this
feature is associated with the outcome.
Similar reasoning is applicable for identifying the covariates’
effect on the event of interest; that is, its positive or negative
contribution for the risk of the therapy failure.
Focusing on the time-independent variables and starting with
the covariate that represents male sex, we can see that this
variable is not statistically significant in any joint or extended
Cox model. This is coherent with what was observed in the Cox
model, where sex was not a statistically significant predictor
for our outcome. Regarding the effect of the variable on the
event of interest, being male was more frequently a good
predictor of biologic therapy survival than a bad predictor
although this ratio was very small for the joint models.
The year of disease beginning was statistically significant for
most models it was present in even if only 1 data set analyzed
this variable. Its associated coefficient was positive for all the
extended Cox models and for an average of 92% (12/13) of the
joint models, which is consistent with the result obtained in the
Cox models, indicating that patients with a more recent onset
of disease have a higher risk of treatment failure.
The year of start of the first biologic therapy appears as a
statistically significant predictor in most joint models and in all
extended Cox models. For the majority of models, biologic
therapy initiated in more recent years appeared to increase the
risk of its failure.
The age at the start of the first biologic was statistically
significant in most joint and extended Cox models, and older
age at the time of therapy initiation was consistently a predictor
of decreased risk of failure.
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The year interval between disease beginning and start of the
first biologic therapy was only statistically significant in a small
percentage of joint models and showed no significance in any
of the extended Cox models, echoing the results for the Cox
model. The coefficient sign for this covariate was coherent
among all models, indicating that a larger year interval reduces
the chance of biologic therapy failure.
Being HLA-B27 positive was statistically significant as a
predictor for biologic therapy failure in approximately 80% of
all models and was consistently associated with a decreased
risk of failure when in comparison with HLA-B27–negative
patients.
The number of years of education showed statistical significance
in roughly 90% of all joint and extended Cox models, and a
higher number of education years increased the hazard of
biologic therapy failure for all Cox, extended Cox, and joint
models.
The value of CRP at baseline had an associated positive
regression coefficient in all joint models and in 80% (4/5) of
extended Cox models, indicating an increased risk of failure
for higher CRP values, which was also verified in the Cox
model. This covariate was not statistically significant in the Cox
regression, but was significant in approximately 40% of the
joint and extended Cox models.
The baseline BASFI was statistically significant in fewer than
half of the joint and extended Cox models, even though it was
always statistically significant in the survival submodels fitted
with a Cox model. This variable appeared to be a predictor for
increased risk of biologic therapy failure in most joint and
extended Cox models, which is concordant with the Cox models'
results.
Regarding the time-dependent variables, we noticed that, for
the joint models, variables CRP, ESR, BASDAI, and ASDAS
appeared to be statistically significant in most models.
Furthermore, all were predictors of increased therapy failure
for all the joint models that were fitted. Variable BASFI was
only statistically significant in approximately half of the joint
models, and the sign of its coefficient also varied considerably,
not showing any clear tendency regarding the effect of this
variable on the outcome.
In the extended Cox models, only variables BASDAI and
ASDAS were statistically significant for all models. Variable
ESR, BASFI, and CRP showed statistical significance in 75%,
58%, and 38% of the models, respectively. In all the models,




Overall, the results obtained from the Cox models, extended
Cox models, and joint models all indicated similar effects of
the covariates on the treatment outcome.
The biomarkers that indicated a good prognosis for the biologic
drug survival were being male, starting biologic therapy at an
older age, having a larger time interval between disease onset
and initiation of the first biologic drug, and being HLA-B27
positive.
Conversely, disease onset or initiation of biologic therapy in
more recent years, a greater number of education years, and
higher values of CRP or BASFI at baseline all appeared to be
predictors of a greater risk of failure of the first biologic therapy.
Comparison With Prior Work
Male sex [22], HLA-B27–positive status [32], and longer disease
duration [21] have been reported in the literature as being good
predictors of biologic drug survival, which concurs with the
results obtained in the Cox models of our study. On the other
hand, older age at the start of the biologic therapy [32] has been
reported to increase the risk of failure of the therapy, which is
contrary to what was found in our data. We could interpret our
result by speculating that older patients are more complacent
due to the perceived efficacy of the therapy or because their
symptoms are more intense than those of younger people and
thus the relative improvement of symptoms is more noticeable,
therefore increasing their satisfaction levels and decreasing the
chances of therapy switch.
Regarding the predictors that were found to increase the risk of
failure in our study, starting treatment in more recent years [33],
and higher values of BASFI at baseline [21] were likewise found
to be predictors of biologic drug discontinuation in research
publications. A higher number of education years [23] was
reported in one study as decreasing the risk of therapy failure,
which differed from our results. Again, we could speculate and
say that patients with a higher academic level are more
comfortable with expressing their discontent with the lack of
therapy response or that they are more aware of new therapeutic
options and for that reason, request a switch of the therapy more
often.
Higher values of CRP at baseline were found to increase [34]
the hazard of biologic therapy failure in some publications but
to have the opposite effect [23,33] in others.
Limitations
Some limitations of our study include the suboptimal fitting of
the longitudinal variables. Therefore, the choice of the LME
function for describing the biomarker trajectories and the
different functional forms available that specify the association
between the longitudinal biomarker and the hazard function of
the event should be further explored.
Conclusions
Joint models are statistical models that can analyze both
time-static and time-varying variables and therefore enable the
inference of relationships between time-to-event and
longitudinal data that are widely present in electronic medical
records.
In this work, this modeling approach was selected to investigate
biologic drug survival and its predictors for SpA patients in
Portugal.
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Furthermore, the insights obtained throughout the process that
culminated in the fitting of these models are also highly
valuable.
This study was the first to use the data of SpA patients from
Reuma.pt in this capacity. The entire preprocessing work
performed for enabling the use of Reuma.pt produced a data set
that can be used by researchers who wish to investigate this
group of diseases.
The variable selection process appears to be sensitive to this
data preprocessing step depending on which variables and
patients are described in the data set.
The tested methods for variable selection yielded quite different
results for the same set of data. The process of selection of
covariates should be analyzed carefully, as fully automated
methods may not be the most appropriate ones for establishing
which variables should be included in the statistical model. A
wise approach consists of a balance between statistical
significance and clinical significance, with the study's goal
always being kept in mind.
We demonstrated that joint models, particularly the functions
implemented in the R software packages “JM” and “Jmbayes,”
can be successfully used for the simultaneous analysis of
time-to-event and longitudinal data.
Health care providers use rheumatic disease progression
measures computed from disease activity scores to shape
treatment strategies and improve the quality of life of their
patients [35]. However, targeted treatments that save patients
from the potential side effects of high-cost, unsatisfactory
treatments require the identification of biomarkers that can
determine which patients can profit from a given therapy [36].
Computational methods using statistical and machine learning
methods hold promise for the overall understanding of rheumatic
diseases and can aid in formulating therapeutic strategies and
predicting prognosis and outcome [37,38].
With this study, it was possible to identify the potential
predictors of biologic therapy failure for this Portuguese
population of SpA patients. This can aid the prognosis of these
rheumatic diseases and potentially predict the most adequate
treatment option according to the patient's characteristics.
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